Previous close | 37.70 |
Open | 37.70 |
Bid | 35.60 |
Ask | 38.60 |
Strike | 165.00 |
Expiry date | 2025-01-17 |
Day's range | 37.70 - 37.70 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.